Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy

Journal of Controlled Release

Volumn 191, Issue , 2014, Pages 82-89

  Mooney, Rachael ^a   Weng, Yiming ^a   Garcia, Elizabeth ^a   Bhojane, Sukhada ^a   Smith Powell, Leslie ^a   Kim, Seung U ^b   Annala, Alexander J ^a   Aboody, Karen S ^a   Berlin, Jacob M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Nanoparticle distribution; Nanoparticle retention; Neural stem cells; Tumor tropism

Indexed keywords

CELLS; CHEMOTHERAPY; CYTOLOGY; NANOPARTICLES; TUMORS;

CLINICAL TREATMENTS; DRUG LOADED NANOPARTICLE; DRUG PENETRATION; HYBRID DELIVERY; INTRATUMORAL DRUG DELIVERIES; NEURAL STEM CELL; TUMOR COVERAGE; TUMOR TROPISMS;

STEM CELLS;

DOCETAXEL; NANOPARTICLE; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; MACROGOL DERIVATIVE; POLY(2-(DIISOPROPYLAMINO)ETHYL METHACRYLATE); POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PH; CELL SURFACE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; HYBRID; INTRATUMORAL DRUG DELIVERY; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CELL MOTION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG SCREENING; FEMALE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; KINETICS; MEDICINAL CHEMISTRY; METABOLISM; NANOMEDICINE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PH; PHARMACEUTICS; PROCEDURES; SCID MOUSE; SOLUBILITY; SURFACE PROPERTY; TRANSPLANTATION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRALESIONAL; KINETICS; MICE; MICE, INBRED NOD; MICE, SCID; NANOMEDICINE; NANOPARTICLES; NEURAL STEM CELLS; POLYETHYLENE GLYCOLS; POLYMERS; POLYMETHACRYLIC ACIDS; SOLUBILITY; SURFACE PROPERTIES; TAXOIDS; TECHNOLOGY, PHARMACEUTICAL; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906949133     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.015     Document Type: Article

References (53)

1. E.P. Goldberg, A.R. Hadba, B.A. Almond, J.S. Marotta, Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery, J. Pharm. Pharmacol. 54 (2002) 159-180.
2. L.M. Good, M.D. Miller, W.A. High, Intralesional agents in the management of cutaneous malignancy: A review, J. Am. Acad. Dermatol. 64 (2011) 413-422.
3. R.J. Mairs, C.L. Wideman, W.J. Angerson, T.L. Whateley, M.S. Reza, J.R. Reeves, L.M. Robertson, A. Neshasteh-Riz, R. Rampling, J. Owens, D. Allan, D.I. Graham, Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model, Br. J. Cancer 82 (2000) 74-80.
4. U. Roelcke, O. Hausmann, A.Merlo, J.Missimer, R.P. Maguire, P. Freitag, E.W. Radu, R. Weinreich, O. Gratzl, K.L. Leenders, PET imaging drug distribution after intratumoral injection: The case for (124)I-iododeoxyuridine in malignant gliomas, J. Nucl. Med. 43 (2002) 1444-1451.
5. A.I. Minchinton, I.F. Tannock, Drug penetration in solid tumours, Nature reviews, Cancer 6 (2006) 583-592.
6. C.H. Heldin, K. Rubin, K. Pietras, A. Ostman, High interstitial fluid pressure - An obstacle in cancer therapy, Nature reviews, Cancer 4 (2004) 806-813.
7. E.K. Orenberg, B.H. Miller, H.T. Greenway, J.A. Koperski, N. Lowe, T. Rosen, D.M. Brown, M. Inui, A.G. Korey, E.E. Luck, The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma, J. Am. Acad. Dermatol. 27 (1992) 723-728.
8. B.A. Almond, A.R. Hadba, S.T. Freeman, B.J. Cuevas, A.M. York, C.J. Detrisac, E.P. Goldberg, Efficacy of mitoxantrone-loaded albumin microspheres for intratumoral chemotherapy of breast cancer, J. Control. Release 91 (2003) 147-155.
9. J.M. Swinehart, M. Sperling, S. Phillips, S. Kraus, S. Gordon, J.M. McCarty, G.F. Webster, R. Skinner, A. Korey, E.K. Orenberg, Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. A phase 3 clinical study, Arch. Dermatol. 133 (1997) 67-73.
10. B.H. Miller, J.S. Shavin, A. Cognetta, R.J. Taylor, S. Salasche, A. Korey, E.K. Orenberg, Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel, J. Am. Acad. Dermatol. 36 (1997) 72-77.
11. H. Holback, Y. Yeo, Intratumoral drug delivery with nanoparticulate carriers, Pharm. Res. 28 (2011) 1819-1830.
12. K.S. Aboody, J. Najbauer, M.Z. Metz, M. D'Apuzzo, M. Gutova, A.J. Annala, T.W. Synold, L.A. Couture, S. Blanchard, R.A. Moats, E. Garcia, S. Aramburo, V.V. Valenzuela, R.T. Frank, M.E. Barish, C.E. Brown, S.U. Kim, B. Badie, J. Portnow, Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies, Sci. Transl. Med. 5 (2013) 84-159.
13. K.S. Aboody, J. Najbauer, M.K. Danks, Stem and progenitor cell-mediated tumor selective gene therapy, Gene Ther. 15 (2008) 739-752.
14. D. Zhao, J. Najbauer, A.J. Annala, E. Garcia, M.Z. Metz, M. Gutova, M.D. Polewski, M. Gilchrist, C.A. Glackin, S.U. Kim, K.S. Aboody, Human neural stem cell tropism to metastatic breast cancer, Stem Cells 30 (2012) 314-325.
15. D.H. Zhao, J. Najbauer, E. Garcia, M.Z. Metz, M. Gutova, C.A. Glackin, S.U. Kim, K.S. Aboody, Neural stemcell tropismto glioma: critical role of tumor hypoxia, Mol. Cancer Res. 6 (2008) 1819-1829.
16. K.S. Aboody, A. Brown, N.G. Rainov, K.A. Bower, S.X. Liu, W. Yang, J.E. Small, U. Herrlinger, V. Ourednik, P.M. Black, X.O. Breakefield, E.Y. Snyder, Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas (vol 97, pg 12846, 2000), Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 777.
17. B. Auffinger, A.U. Ahmed, M.S. Lesniak, Oncolytic virotherapy for malignant glioma: Translating laboratory insights into clinical practice, Front. Oncol. 3 (2013) 32.
18. K. Schnarr, R. Mooney, Y. Weng, D. Zhao, E. Garcia, B. Armstrong, A.J. Annala, S.U. Kim, K.S. Aboody, J.M. Berlin, Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer, Adv. Healthc. Mater. 2 (2013) 976-982.
19. R.T. Frank, M. Edmiston, S.E. Kendall, J. Najbauer, C.W. Cheung, T. Kassa, M.Z.Metz, S. U. Kim, C.A. Glackin, A.M. Wu, P.J. Yazaki, K.S. Aboody, Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies, PLoS One 4 (2009) e8314.
20. K. Aboody, A. Capela, N. Niazi, Jeffrey H. Stern, S. Temple, Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta stone, Neuron 70 (2011) 597-613.
21. R. Mooney, Y. Weng, R. Tirughana-Sambandan, V. Valenzuela, S. Aramburo, E. Garcia, Z. Li, M. Gutova, A.J. Annala, J.M. Berlin, K.S. Aboody, Neural stem cells improve intracranial nanoparticle retention and tumor-selective distribution, Future Oncol. 10 (2014) 401-415.
22. L. Li, Y. Guan, H. Liu, N. Hao, T. Liu, X. Meng, C. Fu, Y. Li, Q. Qu, Y. Zhang, S. Ji, L. Chen, D. Chen, F. Tang, Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy, ACS Nano 5 (2011) 7462-7470.
23. S.J.Madsen, S.K. Baek, A.R.Makkouk, T. Krasieva, H. Hirschberg, Macrophages as cellbased delivery systems for nanoshells in photothermal therapy, Ann. Biomed. Eng. 40 (2012) 507-515.
24. M.T. Stephan, S.B. Stephan, P. Bak, J. Chen, D.J. Irvine, Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles, Biomaterials 33 (2012) 5776-5787.
25. S.U. Kim, Human neural stem cells geneticallymodified for brain repair in neurological disorders, Neuropathology 24 (2004) 159-171.
26. S.U. Kim, E. Nakagawa, K. Hatori, A. Nagai, M.A. Lee, J.H. Bang, Production of immortalized human neural crest stem cells, Methods Mol. Biol. 198 (2002) 55-65.
27. B. Ljujic, M. Milovanovic, V. Volarevic, B. Murray, D. Bugarski, S. Przyborski, N. Arsenijevic, M.L. Lukic, M. Stojkovic, Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice, Sci. Rep. 3 (2013).
28. Y. Krishnamachari, M.E. Pearce, A.K. Salem, Self-assembly of cell-microparticle hybrids, Adv. Mater. 20 (2008) 989-993.
29. G. Paganelli, P. Magnani, F. Zito, E. Villa, F. Sudati, L. Lopalco, C. Rossetti, M. Malcovati, F. Chiolerio, E. Seccamani, et al., Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients, Cancer Res. 51 (1991) 5960-5966.
30. D.S. Kohane, Microparticles and nanoparticles for drug delivery, Biotechnol. Bioeng. 96 (2007) 203-209.
31. W.D. Foulkes, I.E. Smith, J.S. Reis-Filho, Triple-negative breast cancer, N. Engl. J.Med. 363 (2010) 1938-1948.
32. G. von Minckwitz, M. Martin, Neoadjuvant treatments for triple-negative breast cancer (TNBC), Ann. Oncol./ESMO 23 (Suppl. 6) (2012) vi35-vi39.
33. L.G. Estevez, W.J. Gradishar, Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer, Clin. Cancer Res. 10 (2004) 3249-3261.
34. M. Kaufmann, G. von Minckwitz, R. Smith, V. Valero, L. Gianni, W. Eiermann, A. Howell, S.D. Costa, P. Beuzeboc, M. Untch, J.-U. Blohmer, H.-P. Sinn, R. Sittek, R. Souchon, A.H. Tulusan, T. Volm, H.-J. Senn, International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations, J. Clin. Oncol. 21 (2003) 2600-2608.
35. C. Liedtke, C. Mazouni, K.R. Hess, F. Andre, A. Tordai, J.A. Mejia, W.F. Symmans, A.M. Gonzalez-Angulo, B. Hennessy, M. Green, M. Cristofanilli, G.N. Hortobagyi, L. Pusztai, Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer, J. Clin. Oncol. 26 (2008) 1275-1281.
36. L.A. Carey, E.C. Dees, L. Sawyer, L. Gatti, D.T. Moore, F. Collichio, D.W. Ollila, C.I. Sartor, M.L. Graham, C.M. Perou, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin. Cancer Res. 13 (2007) 2329-2334.
37. S. Amat, P. Bougnoux, F. Penault-Llorca, F. Fetissof, H. Cure, F. Kwiatkowski, J.L. Achard, G. Body, J. Dauplat, P. Chollet, Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate, Br. J. Cancer 88 (2003) 1339-1345.
38. A.W.Hutcheon, S.D. Heys, T.K. Sarkar, G. Aberdeen Breast, Neoadjuvant docetaxel in locally advanced breast cancer, Breast Cancer Res. Treat. 79 (Suppl. 1) (2003) S19-S24.
39. Y. Cheng, R. Morshed, S.H. Cheng, A. Tobias, B. Auffinger, D.A.Wainwright, L. Zhang, C. Yunis, Y. Han, C.T. Chen, L.W. Lo, K.S. Aboody, A.U. Ahmed, M.S. Lesniak, Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy, Small 9 (2013) 4123-4129.
40. K. Zhou, Y. Wang, X. Huang, K. Luby-Phelps, B.D. Sumer, J. Gao, Tunable, ultrasensitive pH-responsive nanoparticles targeting specific endocytic organelles in living cells, Angew. Chem. Int. Ed. 50 (2011) 6109-6114.
41. H. Yu, Y. Zou, Y.Wang, X. Huang, G. Huang, B.D. Sumer, D.A. Boothman, J. Gao, Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery, ACS Nano 5 (2011) 9246-9255.
42. L.E. Gerweck, K. Seetharaman, Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer, Cancer Res. 56 (1996) 1194-1198.
43. X. Zhang, Y. Lin, R.J. Gillies, Tumor pH and its measurement, J. Nucl. Med. 51 (2010) 1167-1170.
44. R. Patil, J. Portilla-Arias, H. Ding, B. Konda, A. Rekechenetskiy, S. Inoue, K.L. Black, E. Holler, J.Y. Ljubimova, Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(beta-L-malic acid), Int. J. Mol. Sci. 13 (2012) 11681-11693.
45. D. Zheng, X. Li, H. Xu, X. Lu, Y. Hu, W. Fan, Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma, Acta Biochim. Biophys. Sin. 41 (2009) 578-587.
46. C. Ferlini, G. Scambia, M. Distefano, P. Filippini, G. Isola, A. Riva, E. Bombardelli, A. Fattorossi, P. Benedetti Panici, S. Mancuso, Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines ismediated by the induction of apoptosis, Br. J. Cancer 75 (1997) 884-891.
47. A.K. Suresh, Y. Weng, Z. Li, R. Zerda, D. Van Haute, J.C. Williams, J.M. Berlin, Matrix metalloproteinase-triggered denuding of engineered gold nanoparticles for selective cell uptake, J. Mater. Chem. B 1 (2013) 2341-2349.
48. M.N.A. Bijman, M.P.A. van Berkel, G.P. van Nieuw Amerongen, E. Boven, Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cellmotility, Biochem. Pharmacol. 76 (2008) 707-716.
49. J. Murtagh, H. Lu, E.L. Schwartz, Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation, Cancer Res. 66 (2006) 8192-8199.
50. M.J. Ernsting, W.D. Foltz, E. Undzys, T. Tagami, S.-D. Li, Tumor-targeted drug delivery usingMR-contrasted docetaxel-carboxymethylcellulose nanoparticles, Biomaterials 33 (2012) 3931-3941.
51. M. Murakami, M.J. Ernsting, E. Undzys, N. Holwell, W.D. Foltz, S.D. Li, Docetaxel conjugate nanoparticles that target alpha-smoothmuscle actin-expressing stromal cells suppress breast cancer metastasis, Cancer Res. 73 (2013) 4862-4871.
52. J.A. MacKay, D.F. Deen, F.C. Szoka Jr., Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating, Brain Res. 1035 (2005) 139-153.
53. A.B. Brown, W. Yang, N.O. Schmidt, R. Carroll, K.K. Leishear, N.G. Rainov, P.M. Black, X.O. Breakefield, K.S. Aboody, Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin, Hum. Gene Ther. 14 (18) (2003 Dec 10) 1777-1785.